Nasdaq apls.
If you want to know who really controls Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), then you'll have to look at the makeup of its share registry. Large companies usually have institutions as ...
WALTHAM, Mass. and NANTES, France, June 22, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc (Nasdaq: APLS) and Affilogic today announced that the companies have expanded their research and development (R&D) collaboration, which was initially formed in 2018, to include the development of Nanofitins® targeting …WALTHAM, Mass., July 30, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced data from the GALE extension study following 30 months of continuous treatment with ...Find the latest Financials data for Apellis Pharmaceuticals, Inc. Common Stock (APLS) at Nasdaq.com.NASDAQ:APLS Long Term Investor Notice: Investigation of Potential Wrongdoing at Apellis Pharmaceuticals, Inc. An investigation on behalf of current long term investors in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) shares over possible breaches of fiduciary duty by certain officers and directors was announced.
Nasdaq provides an interactive stock information chart to view history. Downloadable stock history data table is also accessible by clicking on Data Table on the navigation tool bar. If you have ...APLS | Complete Apellis Pharmaceuticals Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.Headline. APLS Jan 2025 120.000 put. finance.yahoo.com - November 23 at 9:19 AM. Apellis Pharmaceuticals (NASDAQ:APLS) Trading Down 3.7% After Insider Selling. americanbankingnews.com - November 23 at 1:49 AM. Alec Machiels Sells 1,250 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Stock. americanbankingnews.com - November 22 at 4:44 AM.
WALTHAM, Mass., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced the closing ...
08/15/2022. Option Execute. Direct. 12,500. $15.09. 55,407. Back to APLS Overview. Insider Trading information for NDAQ is derived from Forms 3 and 4 filings filed with the U.S. Securities and ...Cash and cash equivalents of $765 million as of March 31, 2023; expected cash runway into Q1 2025. WALTHAM, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced its first quarter 2023 financial results and business …Apellis Pharmaceuticals, Inc. (“Apellis”) (NASDAQ:APLS) recently completed an upsized underwritten public offering of 8563830 shares of its common stock at ...Apellis Pharmaceuticals Inc (NASDAQ: APLS) shares are trading lower amid safety concerns regarding the company's newly launched Syfovre (pegcetacoplan injection) for geographic atrophy (GA ...Apellis Pharmaceuticals (NASDAQ:APLS) dropped 8.6% amid a new short call from Citron Research. Citron claims it wouldn't be surprised if the Food and Drug Administration "steps in with a warning ...
Feb 22, 2023 · With the business potentially at an important milestone, we thought we'd take a closer look at Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) future prospects. Apellis Pharmaceuticals, Inc., a ...
Noteworthy Wednesday Option Activity: RUN, APLS, VRT. Among the underlying components of the Russell 3000 index, we saw noteworthy options trading …
May 18, 2023 · deliormanli. Background. Apellis Pharmaceuticals (NASDAQ:APLS), is a US-based commercial biotech focused on innovative biologics that inhibit the complement system via C3 targeting.The firm's ... On October 12, 2023, Brian Cheng, an analyst at BofA Securities, expressed his viewpoint on Apellis Pharmaceuticals (NASDAQ:APLS). Despite maintaining a Neutral rating, Cheng increased the price target for the company from $44 to $46. It is worth noting that Apellis Pharmaceuticals has garnered a Strong Buy consensus among analysts, who have set a …CRESTWOOD, Ky. and WALTHAM, Mass., April 23, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel ...Operating as a commercial-stage biopharmaceutical entity, Apellis Pharmaceuticals (NASDAQ:APLS) is dedicated to the discovery, development, and market introduction of groundbreaking therapeutic ...CRESTWOOD, Ky. and WALTHAM, Mass., Dec. 20, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel ...
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) between January 28, 2021 and July 28, 2023, both dates ...Is Apellis Pharmaceuticals (NASDAQ:APLS) a buy? Compare the latest price, visualised quantitative ratios, annual reports, historical dividends, ...Apellis Pharmaceuticals Insider Sold Shares Worth $444,620, According to a Recent SEC Filing. Nov. 21. MT. Mizuho Raises Price Target on Apellis Pharmaceuticals to $49 From $42, Keeps Neutral Rating. Nov. 13. MT. Goldman Sachs Initiates Apellis Pharmaceuticals at Buy Rating With $74 Price Target.Nov 29, 2023 · That number of contracts represents approximately 5.6 million underlying shares, working out to a sizeable 101.3% of VRT's average daily trading volume over the past month, of 5.5 million shares ... Apellis Pharmaceuticals (NASDAQ:APLS) dropped 8.6% amid a new short call from Citron Research. Citron claims it wouldn't be surprised if the Food and Drug Administration "steps in with a warning ...The APLS shares have gain 13.10% over the last week, with a monthly amount glided 10.71%, and seem to be holding up well over. A share price of Apellis Pharmaceuticals Inc [APLS] is currently trading at $53.87, up 7.10%. An important factor to consider is whether the stock is rising or falling in short-term value. The APLS shares …
Market forces rained on the parade of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) shareholders today, when the analysts downgraded their forecasts for this year. There was a fairly draconian cut ...
WALTHAM, Mass., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that detailed data ...WALTHAM, Mass., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq:APLS), a global biopharmaceutical company and leader in complement, today announced the pricing of its ...WALTHAM, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will ...A few examples include what’s going on with shares of Yellow Corp (OTCMKTS:YELLQ), Nio (NYSE: NIO), and Apellis Pharmaceuticals (NASDAQ: APLS) stock today. You can catch up on all of that news ...Apellis Pharmaceuticals ( NASDAQ: APLS) can't seem to shake off safety concerns with its vision loss drug Syfovre (pegcetacoplan) and is down another ~6% on Tuesday. Adding to the company's woes ...WALTHAM, Mass., Dec. 04, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the ...GA is an advanced form of age-related macular degeneration and a leading cause of blindness that impacts approximately one million AmericansWinkler and his family saw firsthand the impact of vision... -April 17, 2023 at 07:01 am- MarketScreenerApellis Pharmaceuticals APLS WideScreen charts, DMA,SMA,EMA technical analysis, forecast prediction, by indicators ADX,MACD,RSI,CCI NASDAQ stock exchange.Feb 22, 2023 · With the business potentially at an important milestone, we thought we'd take a closer look at Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) future prospects. Apellis Pharmaceuticals, Inc., a ... Since Friday, Apellis Pharmaceuticals Inc (NASDAQ:APLS) shares have plummeted around 50% after the stock came under pressure following the disclosure of safety events connected to Syfovre. Syfovre ...
GA is an advanced form of age-related macular degeneration and a leading cause of blindness that impacts approximately one million AmericansWinkler and his family saw firsthand the impact of vision... -April 17, 2023 at 07:01 am- MarketScreener
On this news, shares of Apellis fell $6.27 per share, or approximately 19.6%, from a close of $32.02 per share on July 28, 2023, to close at $25.75 per share on July 31, 2023. The case is ...
Dec 1, 2023 · The average twelve-month price prediction for Apellis Pharmaceuticals is $66.50 with a high price target of $93.00 and a low price target of $29.00. Learn more on APLS's analyst rating history. Do Wall Street analysts like Apellis Pharmaceuticals more than its competitors? Apellis Pharmaceuticals Inc (NASDAQ: APLS) revealed a comprehensive corporate restructuring plan aimed at catalyzing the growth of its flagship products, Syfovre (pegcetacoplan injection) andWALTHAM, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS) today announced that the company approved the grant of equity awards to 20 new employees with a ...09/12/2022. 10.34%. 81,049,608. 8,376,486. 1,299,519. 6.45. Data brought to you by Benzinga APIs. Looking for the most shorted stocks? Short interest for Apellis Pharmaceuticals gives investors a ...WALTHAM, Mass., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will ...Apellis Pharmaceuticals, Inc. (“Apellis”) (NASDAQ:APLS) recently completed an upsized underwritten public offering of 10062500 shares of its common stock at ...USA. Published on June 4, 2021. venBio, a Palo Alto, CA and San Francisco, CA-based closed its fourth life sciences venture capital fund, venBio Global Strategic Fund IV, LP, at approximately ...Records 1 - 18 of 20 ... Find the latest historical data for Apellis Pharmaceuticals, Inc. Common Stock (APLS) at Nasdaq.com.
WALTHAM, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced its first ...Apellis Pharmaceuticals Inc (Symbol: APLS) saw options trading volume of 11,658 contracts, representing approximately 1.2 million underlying shares or approximately 61.6% of APLS's average daily ...WALTHAM, Mass., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will ...Nov 2, 2023 · Apellis Pharmaceuticals, Inc. APLS reported third-quarter 2023 loss of $1.17 per share, which was wider than the Zacks Consensus Estimate of a loss of 84 cents. The company had reported a loss of ... Instagram:https://instagram. top offshore forex brokersarrived home reviewdoes robinhood have shiba inuvestis uniform Nov 19, 2023 · Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, cold agglutinin ... Analyst Price Forecast Suggests 156.95% Upside. As of July 6, 2023, the average one-year price target for Apellis Pharmaceuticals is 104.04. The forecasts range from a low of 76.76 to a high of ... virtual day tradingtop retirement mutual funds Noteworthy Wednesday Option Activity: RUN, APLS, VRT. Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Sunrun Inc (Symbol: RUN), where a ...APLS technical analysis. This gauge displays a real-time technical analysis overview for your selected timeframe. The summary of Apellis Pharmaceuticals, Inc. is based on the … toro stocks Envestnet Asset Management Inc. lifted its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 2.7% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 21,305 shares of the company’s stock after acquiring an additional 561 shares during the quarter. Envestnet Asset Management […]Apellis Pharmaceuticals (NASDAQ: APLS) 2% HIGHER; BofA Securities upgraded the stock from Neutral to Buy with a price target of $85.00 (from $52.00). After-hours movers: GitLab surges on earnings ...Noteworthy Wednesday Option Activity: RUN, APLS, VRT. Among the underlying components of the Russell 3000 index, we saw noteworthy options trading …